Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Provided By PR Newswire

Last update: Nov 9, 2023

Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline data anticipated in H2 2024